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Abstract
Objective: Hyperpolarization- activated cyclic nucleotide- gated (HCN) channels are 
known to be involved in the generation of absence seizures (ASs), and there is evi-
dence that cortical and thalamic HCN channel dysfunctions may have a proabsence 
role. Many HCN channel blockers are available, but their role in ASs has been inves-
tigated only by localized brain injection or in in vitro model systems due to their lim-
ited brain availability. Here, we investigated the effect on ASs of orally administered 
ivabradine (an HCN channel blocker approved for the treatment of heart failure in 
humans) following injection of the P- glycoprotein inhibitor elacridar, which is known 
to increase penetration into the brain of drug substrates for this efflux transporter. The 
action of ivabradine was also tested following in vivo microinjection into the cortical 
initiation network (CIN) of the somatosensory cortex and in the thalamic ventrobasal 
nucleus (VB) as well as on cortical and thalamocortical neurons in brain slices.
Methods: We used electroencephalographic recordings in freely moving Genetic 
Absence Epilepsy Rats From Strasbourg (GAERSs) to assess the action of oral ad-
ministration of ivabradine, with and without elacridar, on ASs. Ivabradine was also 
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1 |  INTRODUCTION
Absence seizures (ASs) are characterized by loss of con-
sciousness and lack of voluntary movements accompanied 
by generalized spike- and- wave discharges (SWDs) in the 
electroencephalogram (EEG). ASs are present in several 
epilepsies and are the only clinical symptom of childhood 
absence epilepsy (CAE),1,2 which accounts for 10%– 17% 
of all children with epilepsy3 and carries a burdensome per-
sonal, familial, and societal impact.4,5 The first- line therapy 
for CAE is ethosuximide monotherapy, followed by valproic 
acid or lamotrigine,6 but about 30% of CAE children are 
pharmacoresistant, resulting in polytherapy and a consequent 
marked increase in adverse effects.7– 9 Furthermore, about 
60% of children with AS experience neuropsychiatric comor-
bidities (mainly attention/cognitive impairments), which can 
be present before the epilepsy diagnosis, and can even be ag-
gravated following full pharmacological control of ASs.10,11 
Hence, there is a pressing need to find new effective targets 
for AS treatment.
The role for hyperpolarization- activated cyclic nucleotide- 
gated (HCN) channels in ASs has been extensively investi-
gated, with many studies reporting a gain or loss of function, 
mainly involving HCN1 and HCN2 subtypes. In particular, 
analysis of recombinant HCN2 variants in humans with fe-
brile seizures and genetic epilepsy with febrile seizures plus 
shows an increased hyperpolarization- activated current (Ih), 
the current generated by HCN channels.12 Moreover, several 
HCN1 variants have been identified in children with early 
infantile epileptic encephalopathy that lead to either a gain 
or a loss of function,13 whereas in sporadic idiopathic gener-
alized epilepsy patients, point mutations of HCN2 give rise 
to a channel loss of function.14 The diversity of these HCN 
channel dysregulations, however, together with the finding 
that ASs are not the only phenotype present in these patient 
cohorts, makes it difficult to draw any firm conclusion on the 
precise role of HCN channels in human ASs.
Studies in experimental animals have also demonstrated 
a critical role for HCN channels in ASs, but the results are 
often contradictory. Global knockout of HCN115 or HCN216 
elicits ASs, suggesting an antiabsence role of these chan-
nels. Furthermore, two genetic AS models showed both an 
increased thalamic and a decreased cortical Ih as well as a 
contrasting up- or downregulation of HCN1 in both thalamus 
and cortex,17– 20 two brain regions that are essential for AS 
generation.21,22 Moreover, removal of the cyclic adenosine 
monophosphate (cAMP)- sensitivity of HCN2 in the whole 
brain or thalamic ventrobasal nucleus (VB)- selective HCN2 
knockdown leads to ASs,23 whereas VB- selective HCN4 
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microinjected into the CIN and VB of GAERSs in vivo and applied to Wistar CIN and 
GAERS VB slices while recording patch- clamped cortical Layer 5/6 and thalamocor-
tical neurons, respectively.
Results: Oral administration of ivabradine markedly and dose- dependently reduced 
ASs. Ivabradine injection into CIN abolished ASs and elicited small- amplitude 
4– 7- Hz waves (without spikes), whereas in the VB it was less potent. Moreover, 
ivabradine applied to GAERS VB and Wistar CIN slices selectively decreased HCN 
channel- dependent properties of cortical Layer 5/6 pyramidal and thalamocortical 
neurons, respectively.
Significance: These results provide the first demonstration of the antiabsence action 
of a systemically administered HCN channel blocker, indicating the potential of this 
class of drugs as a novel therapeutic avenue for ASs.
K E Y W O R D S
childhood absence epilepsy, cortex, Ih current, thalamocortical neurons, thalamus
Key Points
• Systemic administration of ivabradine prevents 
absence seizures by blocking neuronal HCN 
channels
• Ivabradine injected in the cortical initiation net-
work abolishes absence seizures, whereas its an-
tiabsence effect is smaller when injected in the 
ventrobasal thalamus
• HCN channel blockade by ivabradine affects 
membrane properties of cortical Layer 5/6 pyram-
idal and thalamocortical neurons
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knockdown has no effect.24 Conversely, pharmacological and 
genetic suppression of HCN channels in the VB suppressed 
ASs in three animal models, suggesting that HCN channels in 
this brain region have a proabsence role.25
Notwithstanding the therapeutic potential of targeting HCN 
channels for the treatment of ASs, an HCN channel modulator 
must show efficacy following systemic administration for it to 
have clinical applicability. Several HCN channel blockers have 
been developed so far,26 including ivabradine (IVA; Procoralan, 
Corlanor), a drug approved for the treatment of heart failure.27– 29 
All these HCN channel blockers, however, show a very limited 
ability to cross the blood– brain barrier (BBB), due to the ef-
flux mediated by P- glycoproteins (Pgp). Thus, whereas HCN 
channel blockers have been extensively used to inhibit neuronal 
HCN channels in vitro,30 the interpretation of the few brain in-
vestigations that used systemic administration are questionable 
due to their poor brain penetration.31– 33
Here, we show for the first time that IVA orally adminis-
tered together with elacridar (ELA), a Pgp inhibitor,34 elicits a 
marked and long- lasting reduction of ASs in a well- established 
AS model (the Genetic Absence Epilepsy Rats From Strasbourg 
[GAERSs]).35 Additionally, a similar antiabsence action occurs 
when IVA is directly injected into the cortical initiation net-
work (CIN)36 and the VB, and IVA selectively decreases HCN 
channel- dependent properties of cortical Layer 5/6 pyramidal 
and VB thalamocortical neurons in vitro.
2 |  MATERIALS AND METHODS
2.1 | Animals
GAERSs (originally obtained from Strasbourg, France) 
were bred and maintained at Cardiff University (UK) and 
University of Szeged (Hungary). Wistar rats (originally from 
Envigo) were maintained at H. Lundbeck (Copenhagen, 
Denmark) and University of Szeged (Szeged, Hungary). 
Animals were provided with normal diet and water ad libi-
tum, and kept under a light:dark cycle of 12:12 h with light 
on at 7:00  a.m. Experimental procedures were performed 
in agreement with the UK Animals (Scientific Procedures) 
Act (1986), the European Communities Council Directive 
(2010/63/EU), and the Danish legislation (Law and Order 
on Animal Experiments; Act No. 474 of May 15, 2014 and 
Order No. 12 of January 7, 2016).
2.2 | IVA plasma and brain bioanalysis
Plasma and brain concentrations of IVA were measured in 
3- month- old male Wistar rats 1  h after injection to assess 
its concentration at the time of the ELA peak brain concen-
tration, and in 3– 4- month old male GAERSs 2  h after the 
injection (i.e., at the end of the recording session) to measure 
brain IVA concentration at the time of the last recording pe-
riod (see below). Blood samples were kept in 1.6- mg EDTA/
ml of blood, centrifuged at 3300 × g for 15 min at 4°C, and 
stored at −80°C until bioanalysis. Brains were stored at 
−80°C until bioanalysis.
Brain samples were prepared by homogenizing half brain 
using isothermal focused acoustic ultrasonication (Covaris 
E220x) as described previously.37 After homogenization, 
calibration standards and quality control (QC) samples were 
prepared in blank rat plasma and brain homogenate in the 
range of .5– 500 ng/ml. On the day of analysis, 25 µl of brain 
homogenates, plasma samples, calibration standards, and QC 
samples were precipitated with 100 µl acetonitrile containing 
internal standard. After centrifugation (20 min at 3500 × g), 
50 µl supernatant was transferred to a 300- µl 96- well plate 
and mixed with 150 µl 25% acetonitrile solution.
IVA concentrations were determined using ultraperfor-
mance liquid chromatography (Waters ACQUITY UPLC 
System) coupled to a tandem mass spectrometry detector 
(Waters Xevo TQ- XS). Chromatographic separation was 
performed on a Waters C18SB HSS column (30 × 2.1 mm, 
1.8- μm particles) with a column compartment temperature 
of 40°C using gradient elution with mobile phases consist-
ing of .1% formic acid in water and .1% formic acid in ace-
tonitrile. Autosampler temperature was 10°C, and injection 
volume was 5  µl. Electrospray ionization was performed 
in positive mode. For IVA, the ion 469.3+→262.1+ was 
monitored.
2.3 | Surgical procedures
Adult male GAERSs (250– 300  g) were anesthetized with 
isoflurane (2%– 5%), and body temperature was maintained 
at 37°C with a heating pad. Six gold- plated epidural screws 
(Svenska Dentorama) were implanted in pairs, at frontal, pa-
rietal, and cerebellar sites. For microinjection into the VB and 
CIN, one 8- mm- long guide cannula (Bilaney C315G/50- 99) 
was also implanted in both hemispheres (VB: anteroposterior 
[AP] −3.2, mediolateral [ML] ±3.6, dorsoventral [DV] 4.5, 
with a 5° angle; CIN: AP −2.52, ML ±4.8, DV 1.3, [mm 
from Bregma]).38 The animals were allowed to recover for at 
least 5 days prior to experiments.
2.4 | EEG recordings
The day before experiments, rats were connected to the re-
cording apparatus and placed individually in a plexiglass box 
within a Faraday cage for 1– 2- h habituation. On the day of the 
recordings, animals were placed into the plexiglass box for 
30 min (habituation period) followed by 40 min of recording 
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(control period). They were then transferred to an anesthe-
sia induction chamber, slightly anesthetized with isoflurane 
(1%) and injected intravenously with either ELA (5 mg/kg, 
5 ml/kg) or vehicle (VEH1; hydroxypropyl- β- cyclodextrin) 
as soon as the righting reflex was lost. Anesthesia was 
then terminated, and 20 min after the intravenous ELA (or 
VEH1) administration, the animals received either IVA (10, 
20 or 30  mg/kg) or vehicle (VEH2; 5% D- glucose in dis-
tilled water) orally. Rats were then placed in the plexiglass 
box, reconnected to the EEG apparatus, and recorded for 
2 h while being continuously monitored by one researcher. 
Drug- treatments (VEH1- VEH2, ELA- VEH2, VEH1- IVA, 
and ELA- IVA) were assigned in a pseudorandom manner 
with a crossover design. Each animal received a maximum 
of four different treatments with at least 5 days between each 
treatment.
For microinjection experiments, on the day of the ex-
periment the animals were recorded for 1  h (control pe-
riod), followed by the bilateral insertion of a 9- mm (Bilaney 
C315I/20- 49) cannula, which was connected to a micropump 
(Linton Instruments CMA 400). Animals were then injected 
with either artificial cerebrospinal fluid (aCSF) or IVA (6 
nmol) using a flow rate of .25 µl/min for 2 min and recorded 
for 2 h.
To check cannulae position, brains were collected and 
washed in phosphate- buffered saline (10 mmol·L– 1) followed 
by fixation in 4% paraformaldehyde for 24 h. After fixation, 
100- µm coronal slices were cut from the region containing 
the CIN or VB and then mounted with VECTASHIELD 
Antifade Mounting Media (Vector Laboratories). Slices were 
imaged within the next 24 h and photographed with a BX61 
microscope (Olympus) with a ×4 objective. Results from an-
imals with misplaced cannulae position were not included in 
the final analysis.
2.5 | Data acquisition and analysis
2.5.1 | SWD detection
The analog EEG signal was acquired through a four- 
channel differential preamplifier (high- pass filter .1 Hz; 
SuperTech) connected to a four- channel BioAmp ampli-
fier (1000 gain, low- pass filter 500 Hz; SuperTech) and 
digitized at 1000 Hz using a CED Mk3 1401 (Cambridge 
Electronic Design). SWDs were initially detected semi-
automatically using the SeizureDetect script (kindly pro-
vided by Steve Clifford, Cambridge Electronic Design) 
in Spike2 v7.03 (Cambridge Electronic Design), and 
then checked by visual inspection. Data were digitally 
processed, and an interictal EEG period of wakeful-
ness was manually selected and used to set a threshold 
of ±5– 8 SD of the baseline EEG. To identify SWDs, 
all crossings above or below the threshold were then 
grouped into bursts according to five preset parameters: 
a maximum onset interval (.2  s), a maximum interval 
(.75 s), a minimum number of spikes (five), a minimum 
interval within bursts (1  s), and a minimum duration 
(.6  s). Identified bursts lasting less than 1 s were dis-
carded. The putative bursts were ultimately classified 
into SWDs according to the frequency, which was man-
ually set between 5 and 12  Hz to exclude deep sleep 
epochs or artifacts. This semiautomatic detection was 
further refined by visual inspection. The following pa-
rameters were extracted from the EEG data in 20- min 
epochs: the total time spent in seizure, the total num-
ber of seizures, and the average duration of a seizure. 
Treatment data were normalized to the respective con-
trol period, and statistical analysis was performed after 
normalization (see Section 2.6).
2.5.2 | Power spectral analysis
The Welch power spectral density analysis was performed 
with MATLAB (R2019a; MathWorks) on interictal EEG 
periods that were devoid of ASs in GAERSs treated with 
oral administration of IVA and other drug combinations. 
Change of power spectrum density between control and 
treatment periods was measured as baseline percentage. 
Statistical analysis was performed after normalization to 
the respective control period (see Section 2.6). Similar 
power spectra were performed on the EEG of GAERSs that 
received IVA directly in the CIN and VB, and compared to 
VEH injection.
2.5.3 | Cortical and thalamic slice preparation, 
whole- cell recordings, and data analysis
Male Wistar rats and GAERSs (both 25– 35 days old) were 
anesthetized (ketamine/xylazine, 80/8  mg/kg), their brains 
were quickly sliced (320 µm thickness) in the coronal plane, 
and slices containing either the CIN or the VB were incu-
bated at room temperature (20°C) in aCSF containing (in 
mmol·L– 1) 130 NaCl, 3.5 KCl, 1 NaH2PO4, 24 NaHCO3, 1 
CaCl2, 3 MgSO4, 10 glucose. For recording, slices were sub-
merged in a chamber perfused with a warmed (35°C) con-
tinuously oxygenated (95% O2, 5% CO2) aCSF containing 
(in mmol·L– 1) 130 NaCl, 3.5 KCl, 1 KH2PO4, 24 NaHCO3, 1 
MgSO4, 2 CaCl2, and 10 glucose.
Whole- cell patch- clamp recordings were performed 
using an EPC9 amplifier (Heka Elektronik). Patch pi-
pettes (tip resistance = 4– 5 MΩ) were filled with an in-
ternal solution containing the following (in mmol·L– 1): 
126  K- gluconate, 4 KCl, 4 adenosine triphosphate– Mg, 
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.3 guanosine triphosphate– Na2, 10 hydroxyethylpipera-
zine ethane sulfonic acid, 10 creatine phosphate (pH 7.25, 
osmolarity = 275  mOsm). The liquid junction potential 
(−13  mV) was corrected offline. Access and series re-
sistances were constantly monitored, and data from neu-
rons with a greater than 20% change from the initial value 
were discarded. Action potential amplitude was measured 
from threshold (20  mV/ms on the first derivative of the 
membrane potential) to the peak of the action potential. 
Analysis of these whole- cell data was performed using cus-
tom routines written in Igor.
2.6 | Statistical analysis
Statistical analysis was performed using Prism version 9.0 
(GraphPad Software). Normality of the data was verified 
with a Q- Q plot. The comparison between the two doses 
of ELA was performed using an unpaired t- test assum-
ing equal variances between the two groups. The effect 
of each treatment on SWDs following systemic injection 
was assessed by repeated- measurement two- way analysis 
of variance (ANOVA) using Sidak correction for multiple 
comparisons. The main effect of treatment versus vehicle 
was also measured as area under the curve (AUC) and ana-
lyzed with one- way ANOVA using Dunnett multiple com-
parisons test. Statistical analysis of the power spectra was 
carried out with one- sided Wilcoxon test comparing treat-
ment with control. The main effect of IVA versus aCSF 
for CIN and VB microinjections was assessed by two- way 
ANOVA for multiple timepoints and unpaired t- test for 
AUC. Data from in vitro recordings in cortical and tha-
lamic neurons were analyzed with Wilcoxon signed rank 
test.
All quantitative data in the text and figures are reported as 
mean ± SEM, unless stated otherwise.
2.7 | Drugs
IVA (3- [3- ({[(7S)- 3,4- dimethoxybicyclo[4.2.0]octa- 1,3,5- 
 trien- 7- yl]methyl}(methyl) amino) propyl]- 7,8- dimethoxy- 
2,3,4,5- tetrahydro- 1H- 3- benzazepin- 2- one hydrochloride) 
and ELA (N- [4- [2- (3,4- dihydro- 6,7- dimethoxy- 2(1H)- 
isoquinolinyl)ethyl]phenyl]- 9,10- dihydro- 5- methoxy- 
9- oxo- 4- acridinecarboxamide) were purchased from 
Sigma- Aldrich. For systemic injections, IVA was dis-
solved in a 5% D- glucose (Sigma- Aldrich) solution, and 
the pH was adjusted to 4. ELA was dissolved in 10% 
hydroxypropyl- β- cyclodextrin, and the pH was adjusted to 
4. For local microinjections, IVA was diluted in aCSF. All 
drugs were freshly prepared on each day of experiments.
3 |  RESULTS
3.1 | Systemic injection of IVA
The highest dose of IVA (30 mg/kg) used in this study was 
selected on the basis of its efficacy and safety as described 
in previous European Medicines Agency and US Food and 
Drug Administration reports.27,28 For selecting a dose of 
ELA that could lead to suitable brain levels of IVA, we tested 
two doses of ELA that had been previously reported to allow 
good brain penetration of other systemically dosed Pgp sub-
strates.39 Intravenous pretreatment of Wistar rats with 5 mg/
kg ELA provided higher brain concentration of orally ad-
ministered IVA (622 ± 107 ng/g,) compared to 2.5 mg/kg 
ELA (259 ± 57.6 ng/g, p = .018; Figure 1A). Similarly, the 
brain free concentration of IVA was higher in animals pre-
treated with 5 mg/kg than 2.5 mg/kg ELA (307 ± 53.0 and 
128 ± 28.4 nmol·L– 1, respectively, p = .018), showing a di-
rect correlation with the total drug concentration (Figure 1B). 
No significant differences in the IVA plasma levels were 
observed in animals pretreated with 2.5 and 5 mg/kg ELA 
(p = .603; Figure 1A,B). A dose of 5 mg/kg ELA was thus 
used in further experiments.
We next investigated the effect of orally administered 
IVA on spontaneous ASs in freely moving GAERSs. No 
gross behavioral changes were observed in any treatment 
group during the EEG recordings described below. As 
shown in Figure 2A, in animals pretreated with 5  mg/kg 
ELA, oral administration of 20 and 30 (but not 10) mg/
kg IVA markedly reduced spontaneous ASs, an effect that 
for the highest dose was visible as early as 20  min after 
IVA administration and lasted for the entire duration of 
the recorded period (2  h). Statistical analysis of the nor-
malized AUC of the entire test period showed a signifi-
cant reduction (62%) of the total time spent in seizures for 
the ELA + IVA30 group (.38 ± .09, F = 8.77, DFn = 5, 
DFd  =  22, p  =  .0044), but not for the ELA  +  IVA20 
(.53 ± .09, p = .07), ELA + IVA10 (1.05 ± .09, p > .99), 
ELA + VEH2 (1.2 ± .16, p = .61), and VEH1 + IVA groups 
(1.12 ± .11, p = .86) compared to VEH1 + VEH2 (Figure 
2B1). The mean duration of the seizures was also signifi-
cantly decreased (F = 6.67, DFn = 5, DFd = 22, 41%) in 
the ELA  +  IVA30 group (.59  ±  .07, p  =  .008), but not 
in the ELA + IVA20 (.66 ± .09, p = .09), ELA + IVA10 
(1.03 ± .1, p > .99), ELA + VEH2 (1.06 ± .08, p > .99), 
and VEH1 + IVA groups (1.06 ± .09, p = .95) compared 
to VEH1  +  VEH2 (Figure 2B2). Moreover, the number 
of seizures showed a significant decrease (45%) in rats 
treated with ELA + IVA30 (.55 ± .09, F = 4.35, DFn = 5, 
DFd = 46, p = .01) but not in the ELA + IVA20 (.71 ± .09, 
p = .24), ELA + IVA10 (.99 ± .09, p > .99), ELA + VEH2 
(1.08 ± .13, p = .98), and VEH1 + IVA groups (1.03 ± .06, 
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p = .99) compared to VEH1 + VEH2 (Figure 2B3). Finally, 
power spectra of the interictal EEG showed the administra-
tion of ELA + IVA30 to elicit a significant increase in the 
power of theta (4– 8 Hz) and low gamma (30– 50 Hz) fre-
quency bands compared to the VEH1 + VEH2 group and 
a small decrease in the alpha band (8– 14 Hz; Figure 2C).
At the end of the last recording session, the brain and 
plasma of those rats that had received ELA  +  IVA30 or 
VEH + IVA30 as their last treatment were collected to de-
termine the IVA plasma and brain levels. As shown in Figure 
1C, the total plasma concentrations of IVA measured 2  h 
after dosing were in the same range in the two treatment 
groups (VEH1  +  IVA30: 107  ±  19  ng/ml; ELA  +  IVA30 
212 ± 39 ng/ml), whereas the brain concentration was substan-
tially higher in the animals that were dosed with ELA- IVA30 
(373 ± 137 ng/g) compared to those with VEH1 + IVA30 
F I G U R E  1  Brain and plasma levels of systemically injected ivabradine (IVA) with and without pretreatment with elacridar. (A, B) Total brain 
(black dots) and plasma (white dots) levels (A) and brain and plasma free concentrations (B) measured 1 h after oral administration of IVA (30 mg/
kg) in Wistar rats (n = 5 for each group) that had been pretreated with intravenous injection of either 2.5 or 5 mg/kg elacridar (ELA) 30 min before 
IVA injection. (C, D) Total brain (black dots) and plasma (white dots) levels (C) and brain and plasma free concentrations (D) of IVA in Genetic 
Absence Epilepsy Rats From Strasbourg treated with vehicle (VEH) 1  + IVA (n = 2) or ELA (5 mg/kg) + IVA (n = 4). Animals were sacrificed at 
the end of the electroencephalographic recordings, that is, 2 h after IVA injection. In A– D, horizontal and vertical lines indicate mean and ±SEM, 
respectively. conc, concentration
F I G U R E  2  Oral administration of ivabradine (IVA) markedly blocks absence seizures. (A) Representative electroencephalographic 
(EEG) traces of four different freely moving Genetic Absence Epilepsy Rats From Strasbourg injected with either vehicle (VEH) 1 + VEH2, 
VEH1 + IVA, elacridar (ELA) + VEH2, ELA + IVA10, ELA + IVA20, or ELA + IVA30. Note the marked reduction in spike- and- wave 
discharges (SWDs) in the ELA + IVA30 group compared to all other groups (a typical SWD is shown enlarged in the top trace on the right). In A 
and the left plots of B1– 3, interruption in the traces is due to the animals being disconnected from the EEG wires for drug administration; ELA (or 
VEH1) was injected at Time −20 min and IVA (or VEH2) at Time 0 (indicated by the black arrow). Data in B1– 3 are normalized to the control 
period (Section 2). (B1) Time– response curves (left graph) and area under the curve (AUC) of the whole treatment period (right graph) of the 
total time spent in seizures for VEH1 + VEH2 (black, n = 9), ELA + VEH2 (red, n = 9), VEH1 + IVA (orange, n = 9), ELA + IVA10 (green, 
n = 6), ELA + IVA20 (blue, n = 8), and ELA + IVA (ocher, n = 11) groups. (B2) Time– response curve (left graph) and AUC (right graph) of the 
whole treatment period of seizure duration for the six treatment groups (color code and number of animals as in B1). (B3) Time– response curve 
(left graph) and AUC (right graph) of the whole treatment period of the number of seizures for the six treatment groups (color code and number of 
animals as in B1). (C) Left graph: Average normalized interictal power spectra of the four treatment groups (number of animals as in B1, except 
VEH1 + VEH2, n = 6). Horizontal bars on top indicate statistical significance (thin line: p < .05; thick line: p < .01). Right graph: representative 
examples of interictal power spectra for individual animals of the VEH1 + VEH2 (black), ELA + VEH2 (red), VEH1 + IVA (orange), and 
ELA + IVA30 (ocher) groups showing both the control period (dashed black line) and the treatment period. *p < .05, **p < .01, ***p < .005, 
****p < .001
   | 7IACONE Et Al.
8 |   IACONE Et Al.
(9.5  ±  .3  ng/g). The free brain concentration of IVA was 
4.7 ± .1 nmol·L– 1 for VEH1 + IVA30 and 184 ± 67.8 nmo-
l·L– 1 for the ELA + IVA30 group (Figure 1D).
3.2 | Local microinjection of IVA
Because ASs are generated by abnormal firing in cortico-
thalamocortical circuits, we next investigated whether the 
antiabsence effect of systemically administered IVA was 
mediated by an action on thalamic and/or cortical regions. 
Thus, we applied IVA by bilateral microinjection into the VB 
or CIN of freely moving GAERSs.
Bilateral microinjection of IVA (6 nmol) into the VB 
of freely moving GAERSs reduced ASs compared to VEH 
injection (Figure 3A). Statistical analysis of the AUC of 
the entire test period showed a significant reduction (40%, 
F = 2.61, DFn = 6, DFd = 4, p = .05) of the total time spent 
in seizures of IVA (.6 ± .09) compared to VEH (Figure 3B1). 
The number of seizures decreased (29%, F = 2.99, DFn = 6, 
DFd = 4, p = .011) in rats treated with IVA (.71 ± .05) com-
pared to VEH (Figure 3B2), but the mean duration of seizures 
was unchanged (5%, F = 1.39, DFn = 6, DFd = 4, p = .72; 
.95 ± .12; Figure 3B3).
Microinjection of IVA (6 nmol) in the CIN abolished ASs 
even in the first 20- min period after microinjection, and the 
effect lasted for the entire 2- h posttreatment recording period 
(Figure 4A,C1). The AUC of the total time spent in seizures 
after IVA (.04  ±  .03) microinjection was 96% (F  =  6.23, 
DFn  =  4, DFd  =  4, p  <  .0001) smaller than that of VEH 
(Figure 4C1). Notably, the CIN injection of IVA elicited 
small- amplitude waves (with no spikes) at 4– 7  Hz (Figure 
4A,B); these EEG oscillations were not the electrographic 
expression of Ass, because they were not accompanied by 
motor arrest and the rats kept moving around the cage during 
this EEG activity. The number of seizures showed a 91% 
(F = 4.57, DFn = 4, DFd = 4, p <  .0001) decrease in rats 
treated with IVA (.09  ±  .04% compared to VEH; Figure 
4C2). Likewise, the mean duration of the seizures was also 
decreased by 81% (F = 1.79, DFn = 4, DFd = 4, p = .0002) 
after IVA administration (.19% ±  .08% compared to VEH; 
Figure 4C3).
3.3 | Effect of IVA on cortical and thalamic 
neuron properties
Because the cellular effects of IVA in neurons of key brain 
areas for AS generation have not been studied either in nor-
mal nonepileptic animals or in GAERSs, we investigated the 
ability of this drug to block HCN channel- mediated mem-
brane properties of GAERS VB thalamocortical neurons 
(Figure 5F). To exclude the possibility that any effect of IVA 
might be due to the higher Ih current present in GAERSs, 
we also studied the action of IVA in cortical Layer 5/6 py-
ramidal neurons of normal Wistar rats (Figure 5B). IVA 
(3   µmol·L– 1) blocked the characteristic depolarizing sag 
elicited in these neurons by hyperpolarizing current pulses 
(Figure 5A,C,E,G). Furthermore, IVA hyperpolarized the 
membrane potential of both neuronal types (Figure 5D,H) 
and decreased the number of action potentials evoked by a 
low- threshold spike in thalamocortical and cortical neurons 
(VB: control 5.3 ± .8, IVA 4.5 ± .9, n = 10, p < .05; CIN: 
control 2.5 ± .28, IVA 1.0 ± .4, n = 6, p < .05). In contrast, 
IVA had no effect on the number of action potentials evoked 
by depolarizing current pulses (VB: control 7.9  ±  .4, IVA 
7.6 ± .6, n = 10, p > .05; CIN: control 4.6 ± .2, IVA 4.5 ± .2, 
n = 6, p > .05), and the action potential amplitude (VB: con-
trol 71.2 ± 6.8 mV, IVA 71.4 ± 6.5 mV, n = 11, p > .05; 
CIN: control 78.05  ±  4.75  mV, IVA 80.51  ±  5.32  mV, 
n = 6, p > .05) and threshold (VB: control −51.3 ± 3.3 mV, 
IVA −51.7  ±  2.7  mV, n  =  11, p  >  .05; CIN: control 
−43.7  ±  2.3  mV, IVA  −42.6  ±  2.2  mV, n  =  6, p  >  .05), 
indicating that the effect of this drug is selective on HCN 
channel- mediated membrane properties in both Wistar CIN 
cortical Layer 5/6 pyramidal and GAERS VB thalamocorti-
cal neurons.
4 |  DISCUSSION
Our study provides the first demonstration of the potent 
antiabsence action of systemic administration of the HCN 
channel blocker IVA. Moreover, this drug abolishes and 
reduces ASs when microinjected directly into the CIN and 
VB, respectively, actions mediated by its ability to decrease 
F I G U R E  3  Effect of intrathalamic injection of ivabradine (IVA) on absence seizures. (A) Representative electroencephalographic (EEG) 
traces of two freely moving Genetic Absence Epilepsy Rats From Strasbourg injected in the ventrobasal nucleus with artificial cerebrospinal fluid 
(aCSF) or IVA. In A and left graphs of B1– 3, the break in the traces indicates the period of time when the EEG wires were disconnected to allow 
the exchange of the aCSF with the IVA solution in the injection cannula. aCSF and IVA (6 nmol/side) were injected using a flow rate of .25 µl/
min for 2 min. In B1– 3, data are normalized to the control period. (B1) Time– response curves (left graph) and area under the curve (AUC) of the 
whole treatment period (right plot) of the total time spent in seizures for aCSF (black, n = 7) and IVA (ocher, n = 5) injected animals. (B2) Time– 
response curves (left graph) and AUC of the whole treatment period (right plot) of seizure number of aCSF- and IVA- treated groups (color code 
and number of animals as in B1). (B3) Time– response curves (left graph) and AUC of the whole treatment period (right plot) of seizure duration for 
aCSF- and IVA- treated animals (color code and number of animals as in B1). *p < .05, **p < .01, ***p < .005, ****p < .001. ns, not significant
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Ih- dependent properties of CIN Layer 5/6 pyramidal and VB 
thalamocortical neurons in vitro.
Targeting brain HCN channels in vivo has been a major 
challenge due to the inability of available HCN channel- 
acting drugs to cross the BBB and provide long- lasting 
central nervous system effects. Here, by inhibiting Pgp with 
ELA,34,39,40 we achieved sufficient IVA brain concentrations 
even 2 h after oral administration to affect physiological brain 
rhythms, namely, interictal alpha, theta, and gamma waves, 
and pathological activity, namely, ASs. In the absence of 
10 |   IACONE Et Al.
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ELA pretreatment, IVA failed to alter normal and paroxys-
mal brain oscillations. Notably, the block of Pgp by ELA also 
allowed for the fast antiabsence action of orally administered 
IVA observed in this study. In contrast, IVA decreased phar-
macologically and electrically induced convulsive seizures 
without pretreatment with a drug capable of improving its 
brain absorption.31– 33 IVA brain and plasma levels were not 
measured in these studies, and given our results and previ-
ous evidence of IVA inability to substantially penetrate the 
brain,27– 30 it is at present difficult to explain the IVA anticon-
vulsant action reported in the above studies.
The antiabsence effect of IVA injected into the VB and the 
CIN confirms previous results of the critical role of thalamic 
and cortical HCN channels in ASs.17– 20,25 The effect of IVA 
injected into the CIN is markedly stronger than that follow-
ing oral administration, whereas IVA injection into the VB 
shows a small reduction. In contrast, microdialysis injection 
into the VB of ZD7288, another HCN channel blocker, has 
a strong antiabsence action.25 Although differences in drug 
potency may explain this difference, a much larger portion of 
the VB is undoubtedly affected by continuous 2- h ZD7288 
microdialysis25,41 compared to the more localized 2- min IVA 
microinjected bolus used in the present study.
Our investigation also provides the first in vivo evidence 
that whole- brain block of HCN channels affects normal 
brain oscillations, specifically the interictal increase in theta 
and gamma band power and a shift of the peak of the theta 
frequency band. Theta and gamma oscillations have been 
previously linked to Ih and ASs
42,43, and broad changes in 
corticothalamocortical firing dynamics induced by blocking 
Ih might underlie both the AS block and changes in interic-
tal oscillations. Moreover, IVA injected into the CIN elicits 
small- amplitude waves (with no spikes) at theta frequency 
(4– 7  Hz). The mechanism and pathophysiological signifi-
cance of all waves induced by systemic and intra- CIN injec-
tion of IVA remain to be established.
IVA modulates Ih- dependent membrane properties of 
Wistar cortical Layer 5/6 pyramidal neurons in the CIN and 
GAERS thalamocortical neurons in the VB, namely, the 
depolarizing sag and the resting membrane potential, leav-
ing other membrane properties unaffected, namely, action 
potential threshold and amplitude. As tonic firing was not 
affected by IVA, the decrease of action potential number 
evoked by low- threshold spikes of thalamocortical neurons 
can be explained by the smaller Ih tail current in the pres-
ence of IVA providing a smaller depolarizing contribution 
to low- threshold spikes, which in turn generate fewer action 
potentials.
Our study represents the first proof of principle that 
whole- brain pharmacological block of HCN channels has 
an antiabsence action, and demonstrates for the first time 
that reduction of HCN function selectively in the CIN abol-
ishes ASs, that is, HCN channels of the CIN are necessary 
for AS generation. HCN1 channels are more abundantly 
expressed in cortex than thalamus, whereas HCN2 and 
HCN4 predominate in thalamocortical neurons.24,44 Thus, 
although IVA is a nonselective inhibitor of HCN channel 
isoforms, it is likely that HCN1 may be the isoform un-
derlying its action in the CIN, whereas its VB effects may 
involve an interplay between HCN2 and HCN4. Notably, 
in normal nonepileptic animals, VB- selective knockdown 
of HCN4 does not elicit ASs, whereas VB- selective HCN2 
knockdown, as well as global HCN216 or HCN115 knockout 
(KO), lead to ASs, suggesting an antiabsence role of both 
isoforms. In contrast, our previous study25 and the present 
investigation demonstrate that a genetic and pharmacolog-
ical block of HCN channels in the VB of different mouse 
and rat models decreases ASs. Possible explanations of 
these contradictory results include compensatory changes 
in the full HCN1 and HCN2 KO mice, different species 
used, different potency of HCN blockers against HCN 
channel subtypes, and diverse efficacy/selectivity of ge-
netic versus pharmacological means of manipulating HCN 
channels. The alternative interpretation we suggest here is 
that (1) in normal animals, thalamic HCN2 has an antiab-
sence effect23 and thalamic HCN4 has a proabsence ac-
tion24,45; and (2) in epileptic animals, there is an increased 
contribution of HCN4, with respect to HCN2, to the total Ih 
of thalamocortical neurons. Under this hypothesis, in none-
pileptic animals, VB- selective knockdown of HCN2 elicits 
ASs and VB- selective knockdown of HCN4 does not.23,24 
In genetic AS models, a pharmacological or genetic block 
of all subtypes of thalamic HCN channels would lead to 
an antiabsence effect.25 In support of our hypothesis, (1) 
F I G U R E  4  Effect of intra- cortical initiation network (CIN) injection of ivabradine (IVA) on absence seizures. (A) Representative 
electroencephalographic (EEG) traces of two freely moving Genetic Absence Epilepsy Rats From Strasbourg injected in the CIN with artificial 
cerebrospinal fluid (aCSF) or IVA. In A and left graphs of C1– 3, the break in the traces indicates the period of time when the EEG wires were 
disconnected to allow the exchange of the aCSF with the IVA solution in the injection cannula. aCSF and IVA (6 nmol/side) were injected using a 
flow rate of .25 µl/min for 2 min. In C1– 3, data are normalized to the control period. (B) Average power spectra of intra- CIN injected vehicle and 
IVA (number of animals and color code as in C1). Example of the 4– 7 Hz EEG waveform evoked by IVA is shown on top. (C1) Time– response 
curves (left graph) and area under the curve (AUC) of the whole treatment period (right plot) of the total time spent in seizures for aCSF (black, 
n = 5) and IVA (ocher, n = 5) injected animals. (C2) Time– response curves (left graph) and AUC of the whole treatment period (right plot) of 
seizure number of aCSF- and IVA- treated groups (color code and number of animals as in C1). (C3) Time– response curves (left graph) and AUC 
of the whole treatment period (right plot) of seizure duration for aCSF- and IVA- treated animals (color code and number of animals as in C1). 
*p < .05, **p < .01, ***p < .005, ****p < .001
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in thalamic slices of HCN4 KO mice, there is a reduction 
in electrically evoked intrathalamic oscillations (which are 
considered a proxy of thalamic rhythmic paroxysmal ac-
tivity)24; and (2) an increased Ih is present in VB thalam-
ocortical neurons of GAERSs20 and of normal mice that 
develop atypical ASs following a cortical infarct.45 This in-
creased Ih may result from enhanced HCN channel expres-
sion,17 or from changes in the modulation of this current by 
intracellular messengers (e.g., cAMP)46 and neurotransmit-
ters (e.g., noradrenaline).47 Notably, our hypothesis makes 
the testable predictions that in AS models, a selective block 
of thalamic HCN4 and HCN2 channels should have an an-
tiabsence and no effect on ASs, respectively. The recent 
development of a preferential HCN4 blocker makes it now 
feasible to test this hypothesis.48
In conclusion, acute systemic administration, and 
local cortical and thalamic injection of the HCN chan-
nel blocker IVA abolishes genetically determined ASs in 
a well- established rat model and modulates various in-
terictal thalamocortical rhythms by acting on thalamic 
and cortical Ih- dependent membrane properties. Whereas 
the antiabsence role of another Ih blocker (ZD788) has 
been demonstrated in GAERSs, Stargazer mice, and the 
γ- hydroxybutyrate model,41 the translational significance 
of the present results still needs to be fully investigated. In 
particular, it remains to be established whether a similar 
effect of IVA as shown here in GAERSs is also observed 
in other well- established inbred rat models,49 monogenic 
mouse models,21 and pharmacological models.50 It will 
also be interesting to investigate the effect of IVA on SWDs 
and associated motor arrest (i.e., ASs) that are present in 
various outbred rat strains, although these EEG and be-
havioral abnormalities have been suggested to represent a 
physiological trait,51 a hypothesis strongly rebutted.52– 54 
Moreover, whereas the effects of IVA on various thalamo-
cortical rhythms reported in the present work may restrict 
its clinical potential, selective blockers of HCN channel 
isoforms, which may not affect physiological thalamocorti-
cal oscillations, could represent lead compounds for future 
antiabsence drugs.
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F I G U R E  5  Effect of ivabradine (IVA) on the membrane properties of cortical initiation network (CIN) Layer 5/6 pyramidal and 
ventrobasal nucleus (VB) thalamocortical neurons in vitro. (A) Representative voltage responses of a Wistar CIN Layer 5 pyramidal neuron 
to a hyperpolarizing and depolarizing current step (−200 and 80 pA, respectively) before (control) and during application of 30 µmol·L– 1 IVA 
(membrane potential = −58 mV). Note the decreased depolarizing sag in the presence of IVA. (B) Photomicrograph of the cortical Layer 5 neuron 
from which the electrical recordings shown in A were made. Scale bar = 50 µm. (C) Plot of sag amplitude versus injected current show a decrease 
of the sag in the presence of IVA that is significant for the largest injected currents. (D) Resting membrane potential (RMP) in control conditions 
and in the presence of IVA. Large symbols indicate mean ± SEM. (E) Representative voltage responses of a Genetic Absence Epilepsy Rat 
From Strasbourg VB thalamocortical neuron to a hyperpolarizing and depolarizing current step (−200 and 100 pA, respectively) before (control) 
and during application of 30 µmol·L– 1 IVA (membrane potential = −61 mV). Note the decreased depolarizing sag in the presence of IVA. (F) 
Photomicrograph of the thalamocortical neuron from which the electrical recordings shown in E were made. Scale bar = 50 µm. (G) Plot of sag 
amplitude versus injected current shows a decrease of the sag in the presence of IVA that is significant for the largest injected currents (p < .05). 
(H) RMP in control conditions and in the presence of IVA. Large symbols indicate mean ± SEM. *p < .05
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